RWE: From Regulatory Footnote to the Future of Medical Affairs, Part 2.
July 8, 2026
A Higher Bar, A Wider Net: What ICH M14 and the New RWE Standards Mean for Medical Affairs In Part 1 of this series, we...
Read More
July 8, 2026
A Higher Bar, A Wider Net: What ICH M14 and the New RWE Standards Mean for Medical Affairs In Part 1 of this series, we...
Read More
June 30, 2026
In the fall of 1960, a newly hired pharmacologist named Frances Kelsey received her first assignment at the FDA: review a drug called Kevadon [1]....
Read More
June 23, 2026
Do you ever wonder why pharmaceutical ads on Canadian TV stations are so radically different from US ads? That’s because Canada has distinctly different regulations,...
Read More
June 16, 2026
Many guideline failures are not failures of evidence alone, they are failures of process. Economic constraints, logistical complexity, and political realities exert a profound...
Read More
June 9, 2026
In 2025, a systematic review assessed the methodological rigour of 76 clinical practice guidelines published by the European Society of Cardiology (ESC) and the...
Read More